#United States #Chicago #Immunotherapy #HanchorBio #HCB101

HanchorBio Unveils Promising Data on HCB101 at ASCO 2025

HanchorBio Inc., an emerging leader in immunotherapy biologics, has recently shared encouraging interim results from its groundbreaking cancer treatment, HCB101. This was highlighted at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place from May 31 to June 4 in Chicago, Illinois. Following a successful launch of Phase 2 clinical trials in March, HanchorBio's innovative approach aims to transform cancer treatment paradigms.

Key Findings from the Trials

The interim data presented indicate several significant accomplishments, emphasizing HCB101's potential:
1. Safety and Tolerability: The treatment showcased favorable safety profiles across various escalating doses, suggesting its potential for broad application.
2. CD47 Receptor Occupancy: High-level occupancy of the CD47 receptor in peripheral immune cells was recorded, which is critical in the immune response against tumors.
3. Early Anti-tumor Activity: There are promising early clinical indications of anti-tumor activity, notably in patients suffering from head and neck cancer (HNSCC) and non-Hodgkin's lymphoma, with confirmed cases of partial tumor responses.

What Makes HCB101 Unique?

HCB101 is considered a best-in-class, next-generation checkpoint inhibitor (CPI). CPIs are promising due to their ability to empower the body’s immune system to identify and eliminate cancerous cells. They work by blocking CD47, a protein that enables cancer cells to hide from immune surveillance, often referred to as the 'don't eat me' protein. Compared to traditional chemotherapy, immunotherapy through CPIs is associated with improved long-term remission and broader efficacy across various types of cancers.

Importantly, HCB101 has the distinguished ability to balance efficacy and safety—an area where previous generations of CPIs have struggled. It employs an engineered protein, SIRPα, that targets CD47, showcasing effective treatments for both solid and hematologic tumors. Earlier data from the Phase 1a clinical trial verified a remarkable 100% safety record across all dosage levels, making it a promising candidate for both standalone and combination therapies.

The Phase 1a data indicated a 26.7% disease control rate, with 16.7% of subjects managing to maintain their disease control for longer than four months.

Scott Liu, Ph.D., the founder and CEO of HanchorBio, remarked, "HCB101 addresses the longstanding challenge with traditional CPI treatments, eliminating the trade-off between safety and efficacy. As we advance in our clinical trials, we are paving the way for innovation in immunotherapy that could have profound implications on oncology."

Multi-Region Phase 2 Trials

Currently, HCB101’s Phase 2 trial is ongoing across multiple regions, including Taiwan, the U.S., and China. Earlier this year, the U.S. segment gained approval from the Food and Drug Administration (FDA) to conduct trials through various healthcare institutions. This trial includes participants from diverse backgrounds and encompasses several cancer types, such as lung, stomach, and breast cancers, reinforcing HanchorBio’s commitment to inclusive research.

Impressively Streamlined Development Pipeline

HanchorBio has established a strong reputation for delivering timely results in a relatively short period. The company achieved investigational new drug (IND) status in just 2.3 years, facilitating the acquisition of $80 million in funding. This accomplishment highlights the firm’s distinct capabilities:

• - A Streamlined Pipeline: Simplified processes from discovery to clinical trials enhance efficiency.
• - Expert Team: The company’s workforce combines over 30 years of experience in the pharmaceutical industry, contributing to its innovative edge.
• - Research Facilities: State-of-the-art research and development facilities provide a solid foundation for ongoing projects.

HanchorBio's usage of its proprietary Fc-Based Designer Biologics (FBDB™) platform has further proven successful in transitioning multiple pipeline programs from conceptual stages to clinical evaluations.

As HanchorBio actively seeks to expand its operations and pursue additional funding opportunities, interested stakeholders are encouraged to reach out for potential collaborations.

About HanchorBio

Headquartered in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is committed to leading advancements in immuno-oncology. With an accomplished team of industry veterans, its mission centers around rejuvenating the immune system to combat complex diseases, particularly cancer.

For more updates, visit HanchorBio's website or follow them on LinkedIn.